Close this search box.
Health & Wellness

Entelexo (YC W21)

Creating a new class of drugs to address incurable autoimmune diseases
Investment type:
Target raise:
 - $1,070,000
Minimum investment:​
End date:
Jul 28, 2021

  • >$1M raised to date, plus $310k on the same terms
  • CEO led the 1st clinical trials in the world evaluating exosomes as a treatment for autoimmune disease
  • Targeting 25M affected by immune-mediated diseases in US, equal to ~$150B in medical costs/year
  • Our intellectual property is patent-protected (patent owned by the Company)
Our Story

We are applying new knowledge of stem cell biology to develop new treatments for autoimmune diseases.
Our Ambition

In 5 years we expect to be close to completing phase III clinical trials for our initial products.